Affiliation:
1. Paster St. Petersburg Research Institute of Epidemiology and Microbiology
2. St. Petersburg Phthisiopulmonology Research Institute
3. St. Petersburg Phthisiopulmonology Research Institute,
Abstract
The objective: to study drug susceptibility of M. avium and M. intracellulare isolates received from patients with mycobacteriosis residing in the North Western Federal District using the Sensititre SLOMYCO panels.Subjects and Methods. From 2014 to 2020, 192 slow-growing MAC strains (164 – M. avium, 28 – M. intracellulare) obtained from HIV-negative patients with pulmonary mycobacteriosis were studied. Drug susceptibility testing of MAC strains was performed using the Sensititre SLOMYCO panel consisting of 13 antibacterial drugs.Results. Of the 13 antibacterial drugs, clarithromycin was also most effective against both M. avium (67.1%; 110/164) and M. intracellulare (60.7%; 17/28) (p > 0.05). The proportion of M. avium and M. intracellulare strains sensitive to linezolid was high and amounted to 57.3 and 53.5%, as well as to amikacin – 57.3 and 53.5% respectively.Of the four antibacterial drugs of the Sensititre SLOMYCO panel (clarithromycin, moxifloxacin, linezolid, and amikacin), for which critical concentrations (CC) were established, clarithromycin was the most effective against M. avium and M. intracellulare. Antibiotic-resistant M. avium isolates were more frequent in the group of previously treated patients.
Publisher
LLC "Medical Knowledge and Technologies"
Reference22 articles.
1. Andreevskaya S.N., Larionova E.E., Smirnova T.G. et al. Drug susceptibility of the slow growing non-tuberculous mycobacteria. Tuberculosis and Lung Diseases, 2016, vol. 94, no. 4, pp. 43-50. (In Russ.) https://doi.org/10.21292/2075-1230-2016-94-4-43-50.
2. Starkova D.A., Zhuravlev V.Yu., Vyazovaya A.A. et al. Species diversity of non-tuberculous mycobacteria in patients with mycobacteriosis in the North Western Federal District of Russia. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 6, pp. 16-22. (In Russ.) https://doi.org/10.21292/2075-1230-2019-97-6-16-22
3. Chernousova L.N., Sevastyanova E.V., Larionova E.E. et al. Federalnye klinicheskie rekomendatsii po organizatsii i provedeniyu mikrobiologicheskoy i molekulyarno-geneticheskoy diagnostiki tuberkuleza. [Federal clinical recommendations in organization and implementation of microbiological and molecular-genetic diagnostics of tuberculosis]. Tver, OOO Izdatelstvo Triada Publ., 2015, 46 p.
4. Adachi Y., Tsuyuguchi K., Kobayashi T. et al. Effective treatment for clarithromycin-resistant Mycobacterium avium complex lung disease. J. Infect. Chemother., 2020, vol. 26, no. 7, pp. 676-680. doi: 10.1016/j.jiac.2020.02.008.
5. Brown-Elliott B.A., Iakhiaeva E., Griffith D.E. et al. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J. Clin. Microbiol., 2013, no. 51, pp. 3389e94.